TECP
IKT icon

Trails Edge Capital Partners’s Inhibikase Therapeutics IKT Stock Holding History

Trails Edge Capital Partners’s Portfolio IKT Stock Details IKT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$18.4M Buy
9,051,318
+993,973
+12% +$1.78M 2.92% 16
2026
Q1 		$13.5M Buy
8,057,345
+1,879,221
+30% +$3.34M 3.1% 14
2025
Q4 		$12.7M Buy
+6,178,124
New +$9.83M 3.13% 13

Other funds holding IKT

SCV
Sands Capital Ventures Arlington, Virginia $614M AUM 19.92% 1-Year Est. Return
SCM
Soleus Capital Management Greenwich, Connecticut $2.9B AUM 169.69% 1-Year Est. Return
FFM
Fairmount Funds Management West Conshohocken, Pennsylvania $1.51B AUM 546.08% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
ACM
ADAR1 Capital Management Austin, Texas $2.19B AUM 374.99% 1-Year Est. Return
Blackstone Inc
Blackstone Inc New York $32.9B AUM 23.66% 1-Year Est. Return
SL
Siren LLC Greenwich, Connecticut $4.94B AUM 244.43% 1-Year Est. Return
CC
Commodore Capital New York $1.68B AUM 375.52% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

Trails Edge Capital Partners's IKT Position: Q2 2026 in Review

Trails Edge Capital Partners increased its Inhibikase Therapeutics (IKT) stake by 12% in Q2 2026, buying an estimated $1.78M and bringing the position to 9,051,318 shares worth $18.4M. The position accounts for 2.92% of the portfolio, ranked #16.

Trails Edge Capital Partners first reported a position in IKT in Q4 2025 and has held it in 3 quarters since. 106 funds tracked by Wall St. Rank hold IKT as of Q2 2026.

  • Trails Edge Capital Partners held 9,051,318 shares of Inhibikase Therapeutics worth $18.4M as of Q2 2026.
  • Trails Edge Capital Partners bought 993,973 Inhibikase Therapeutics shares in Q2 2026, an estimated $1.78M.
  • Inhibikase Therapeutics made up 2.92% of Trails Edge Capital Partners's portfolio in Q2 2026, its #16 holding.
  • Trails Edge Capital Partners first reported a position in Inhibikase Therapeutics in Q4 2025 and has held it in 3 quarters since.
  • 106 funds tracked by Wall St. Rank held Inhibikase Therapeutics as of Q2 2026.

Based on Trails Edge Capital Partners's 13F filing for Q2 2026, filed 14 Aug 2026.